Destiny Pharma’s XF-73 anti-bacterial drug delivers encouraging data in US clinical trial
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, sponsored the two-stage study, which was carried out at the NIAID
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.